Reactive arthritis, new approaches to treatment
AUTHORS : Khachumova K.G. | Lytkina K.A.
RELEVANT UNIVERSITIES : Russian State Medical University, Moscow, Russia
YEAR : 2009
Reactive arthritis (ReA) make up 10% of patients in rheumatological hospitals [7], and urogenic
arthritis accounts for 50–75% of all ReA. This is due to the prevalence of sexually transmitted diseases
and the increased level of laboratory diagnostics of urogenic infections, which makes it possible to
establish the correct diagnosis.
The term “reactive arthritis” is used to denote aseptic inflammation in the joints that has
developed in close connection with any infection. In this case, the pathogen and its antigens cannot
be detected in the joint cavity [1]. The most significant etiological factor in the development of
urogenic arthritis is currently recognized as chlamydia (chlamidia trachomatis). Another pathogen is
mycoplasma.